Web Desc
Alzheimer's Disease
Organizer(s): David M. Holtzman, Dora M. Kovacs and Cynthia A. Lemere
Date: March 24 - 29, 2008
Location: Keystone Resort, Keystone, CO, USA
Supported by the Director's Fund
Summary of Meeting:
Aggregation of the amyloid ß peptide and tau in the brain are key events in Alzheimer’s disease (AD). The understanding of the cell biological processes that lead to Aß formation is advancing rapidly. The cellular release, transport, and clearance of Aß and how Aß influences tau are just beginning to be understood. Studies of pathogenesis and treatment of AD with cellular and animal models are promising. Recent data in humans indicates that fluid and imaging biomarkers for both clinical and pre-clinical AD may be possible. Several pivotal issues that remain are: (1) to develop a full understanding of APP, A beta, and tau biology; (2) to be able to predict AD prior to cognitive decline; and (3) to develop effective methods to prevent and treat AD. The goal of this meeting will be to provide a state of the art update of the genetic, molecular, cell biological, and translational aspects of AD. Integration of current and novel bench and translational science in this area should lead to new ideas and collaborations.
Scholarship Deadline: November 26 2007
Discounted Abstract Deadline: November 26 2007
Abstract Deadline: December 26 2007
Discounted Registration Deadline: January 25 2008
We gratefully acknowledge additional support for this conference from:
AlzheimerAlzheimerMerck & Co., Inc.
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Merck & Co., Inc.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Monday, March 24 | 3:00PM - 7:30PM
Registration
Room: Shavano Peak Foyer


Monday, March 24 | 6:30PM - 7:30PM
Refreshments
Room: Shavano Peak Foyer


Monday, March 24 | 7:30PM - 9:15PM
Keynote Session
Room: Red Cloud Peak

Speaker 1 of 2
Christian Haass, Ludwig-Maximilians University Munich, Germany
The Process of Amyloid ß-Peptide generation: Normal and Disease Biology

Monday, March 24 | 7:30PM - 9:15PM
Keynote Session
Room: Red Cloud Peak

Speaker 2 of 2
Dennis J. Selkoe, Harvard Medical School, USA
The End Game in Alzheimer’s Disease: Translating Molecular Mechanisms into Therapeutics

Tuesday, March 25 | 7:00AM - 8:00AM
Breakfast
Room: Shavano/Torreys


Tuesday, March 25 | 8:00AM - 11:00AM
Clinical, Epidemiological, and Genetic Factors Relevant to A
D and Related Disorders

Room: Red Cloud Peak

Speaker 1 of 6
* David M. Holtzman, Washington University, USA

Tuesday, March 25 | 8:00AM - 11:00AM
Clinical, Epidemiological, and Genetic Factors Relevant to A
D and Related Disorders

Room: Red Cloud Peak

Speaker 2 of 6
John Morris, Alzheimer Disease & Associated Disorders, USA
Preclinical AD and PreMCI: The Future of Alzheimer Research

Tuesday, March 25 | 8:00AM - 11:00AM
Clinical, Epidemiological, and Genetic Factors Relevant to A
D and Related Disorders

Room: Red Cloud Peak

Speaker 3 of 6
Rudolph E. Tanzi, Massachusetts General Hospital, USA
The Continuing Search for Novel Alzheimer's Disease Genes

Tuesday, March 25 | 8:00AM - 11:00AM
Clinical, Epidemiological, and Genetic Factors Relevant to A
D and Related Disorders

Room: Red Cloud Peak

Speaker 4 of 6
Lenore J. Launer, National Institute on Aging, USA
Cardiovascular and Non-Genetic Risk Factors for AD

Tuesday, March 25 | 8:00AM - 11:00AM
Clinical, Epidemiological, and Genetic Factors Relevant to A
D and Related Disorders

Room: Red Cloud Peak

Speaker 5 of 6
Elizabeth H. Corder, Duke University, USA
Short Talk: Genetic Risk Profiles for Alzheimer’s Disease: Integration of APOE Genotype and Variants that Up-Regulate Inflammation

Tuesday, March 25 | 8:00AM - 11:00AM
Clinical, Epidemiological, and Genetic Factors Relevant to A
D and Related Disorders

Room: Red Cloud Peak

Speaker 6 of 6
Peter J. Hudson, Avipep Pty Ltd, Australia
Short Talk: Early Stage Alzheimer’s Disease Diagnosis in a Unique Progressing Cohort by Correlation of Cognition, Neuroimaging and Blood Biomarkers (the AIBL Cluster Study).

Tuesday, March 25 | 9:20AM - 9:40AM
Coffee Break
Room: Shavano Peak Foyer


Tuesday, March 25 | 11:00AM - 1:00PM
Poster Setup
Room: Shavano/Torreys


Tuesday, March 25 | 1:00PM - 10:00PM
Poster Viewing
Room: Shavano/Torreys


Tuesday, March 25 | 4:30PM - 5:00PM
Coffee Available
Room: Shavano Peak Foyer


Tuesday, March 25 | 5:00PM - 7:00PM
APP Processing, Function, and Cell Biology of Neurodegenerat
ion

Room: Red Cloud Peak

Speaker 1 of 5
* Cynthia A. Lemere, Brigham and Women's Hospital, Harvard Medical School, USA

Tuesday, March 25 | 5:00PM - 7:00PM
APP Processing, Function, and Cell Biology of Neurodegenerat
ion

Room: Red Cloud Peak

Speaker 2 of 5
Huaxi Xu, Sanford Burnham Prebys Medical Discovery Institute, USA
Pathophysiological Functions of APP: A Potential Function of APP Metabolite AICD in EGFR Signaling and Apoptotic Neuronal Cell Death

Tuesday, March 25 | 5:00PM - 7:00PM
APP Processing, Function, and Cell Biology of Neurodegenerat
ion

Room: Red Cloud Peak

Speaker 3 of 5
Gopal Thinakaran, University of Chicago, USA
APP Processing in Lipid Rafts

Tuesday, March 25 | 5:00PM - 7:00PM
APP Processing, Function, and Cell Biology of Neurodegenerat
ion

Room: Red Cloud Peak

Speaker 4 of 5
Hui Zheng, Baylor College of Medicine, USA
Role of APP in Synaptic Structure and Function

Tuesday, March 25 | 5:00PM - 7:00PM
APP Processing, Function, and Cell Biology of Neurodegenerat
ion

Room: Red Cloud Peak

Speaker 5 of 5
Patricia V. Burgos, NICHD, National Institutes of Health, USA
Short Talk: The AP4 Complex Mediates Sorting of the Amyloid Precursor Protein at the trans-Golgi Network

Tuesday, March 25 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Shavano/Torreys


Tuesday, March 25 | 7:30PM - 10:00PM
Poster Session 1
Room: Shavano/Torreys


Wednesday, March 26 | 7:00AM - 8:00AM
Breakfast
Room: Shavano/Torreys


Wednesday, March 26 | 8:00AM - 11:15AM
Abeta Metabolism, CAA, and Blood-Brain-Barrier
Room: Red Cloud Peak

Speaker 1 of 6
* Cynthia A. Lemere, Brigham and Women's Hospital, Harvard Medical School, USA

Wednesday, March 26 | 8:00AM - 11:15AM
Abeta Metabolism, CAA, and Blood-Brain-Barrier
Room: Red Cloud Peak

Speaker 2 of 6
Randall Bateman, Washington University School of Medicine, USA
APP/Abeta Synthesis and Clearance in Humans

Wednesday, March 26 | 8:00AM - 11:15AM
Abeta Metabolism, CAA, and Blood-Brain-Barrier
Room: Red Cloud Peak

Speaker 3 of 6
Mathias Jucker, Hertie-Institute for Clinical Brain Research and DZNE, Germany
Mouse Models of Cerebral Abeta and Non-Abeta Amyloid Angiopathies

Wednesday, March 26 | 8:00AM - 11:15AM
Abeta Metabolism, CAA, and Blood-Brain-Barrier
Room: Red Cloud Peak

Speaker 4 of 6
William E. Van Nostrand, Stony Brook University, USA
Tg-SwDI: A Mouse Model to Investigate Cerebral Microvascular Amyloid, Neuroinflammation, and Behavioral Deficits

Wednesday, March 26 | 8:00AM - 11:15AM
Abeta Metabolism, CAA, and Blood-Brain-Barrier
Room: Red Cloud Peak

Speaker 5 of 6
Donna M. Wilcock, Duke University, USA
Short Talk: Neurovascular Unit Changes are Observed in Association with Cerebral Amyloid Angiopathy in Several Mouse Models of Alzheimer’s Disease

Wednesday, March 26 | 8:00AM - 11:15AM
Abeta Metabolism, CAA, and Blood-Brain-Barrier
Room: Red Cloud Peak

Speaker 6 of 6
Bruce T. Lamb, Indiana University School of Medicine, USA
Short Talk: The Role of Inflammation and Beta-Amyloid Oligomers in Triggering Aberrant Neuronal Cell Cycle Events

Wednesday, March 26 | 9:20AM - 9:40AM
Coffee Break
Room: Shavano Peak Foyer


Wednesday, March 26 | 11:15AM - 1:00PM
Poster Setup
Room: Shavano/Torreys


Wednesday, March 26 | 1:00PM - 10:00PM
Poster Viewing
Room: Shavano/Torreys


Wednesday, March 26 | 4:30PM - 5:00PM
Coffee Available
Room: Shavano Peak Foyer


Wednesday, March 26 | 5:00PM - 7:00PM
BACE and Gamma-Secretase
Room: Red Cloud Peak

Speaker 1 of 5
* David M. Holtzman, Washington University, USA

Wednesday, March 26 | 5:00PM - 7:00PM
BACE and Gamma-Secretase
Room: Red Cloud Peak

Speaker 2 of 5
Michael S. Wolfe, Brigham and Women's Hospital, Harvard Medical School, USA
Biochemistry and Inhibition of Gamma-Secretase and Presenilin-like Proteases

Wednesday, March 26 | 5:00PM - 7:00PM
BACE and Gamma-Secretase
Room: Red Cloud Peak

Speaker 3 of 5
Takeshi Iwatsubo, University of Tokyo, Japan
Structure and Function of the gamma-Secretase Complex

Wednesday, March 26 | 5:00PM - 7:00PM
BACE and Gamma-Secretase
Room: Red Cloud Peak

Speaker 4 of 5
Robert J. Vassar, Northwestern University Medical School, USA
The Role of BACE1 in Alzheimer's Disease

Wednesday, March 26 | 5:00PM - 7:00PM
BACE and Gamma-Secretase
Room: Red Cloud Peak

Speaker 5 of 5
Doo Yeon Kim, Harvard Medical School, Massachusetts General Hospital, USA
Short Talk: BACE1 and gamma-Secretase Regulate Voltage-Gated Sodium Channel Metabolism

Wednesday, March 26 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Shavano/Torreys


Wednesday, March 26 | 7:30PM - 10:00PM
Poster Session 2
Room: Shavano/Torreys


Thursday, March 27 | 7:00AM - 8:00AM
Breakfast
Room: Shavano/Torreys


Thursday, March 27 | 8:00AM - 11:15AM
Tau Function and Dysfunction in AD and Related Disorders
Room: Red Cloud Peak

Speaker 1 of 7
* David M. Holtzman, Washington University, USA

Thursday, March 27 | 8:00AM - 11:15AM
Tau Function and Dysfunction in AD and Related Disorders
Room: Red Cloud Peak

Speaker 2 of 7
Kurt R. Brunden, University of Pennsylvania, USA
Tau Focused Drug Discovery for Alzheimer’s Disease and Related Tauopathies

Thursday, March 27 | 8:00AM - 11:15AM
Tau Function and Dysfunction in AD and Related Disorders
Room: Red Cloud Peak

Speaker 3 of 7
Fred Van Leuven, Experimental Genetics Group - KU Leuven, Belgium
Tau Phosphorylation and Tauopathy in Mouse Models: Amyloid Activates GSK3

Thursday, March 27 | 8:00AM - 11:15AM
Tau Function and Dysfunction in AD and Related Disorders
Room: Red Cloud Peak

Speaker 4 of 7
Karen Hsiao Ashe, University of Minnesota, USA
Toward Understanding the Molecular Basis of Tau-induced Memory Loss

Thursday, March 27 | 8:00AM - 11:15AM
Tau Function and Dysfunction in AD and Related Disorders
Room: Red Cloud Peak

Speaker 5 of 7
Erik D. Roberson, University of Alabama at Birmingham, USA
Tau and Neuronal Dysfunction

Thursday, March 27 | 8:00AM - 11:15AM
Tau Function and Dysfunction in AD and Related Disorders
Room: Red Cloud Peak

Speaker 6 of 7
Tudor A. Fulga, Vertex Genetic Therapies, USA
Short Talk: Actin Cytoskeleton – A Critical Mediator of Neuronal Degeneration in Alzheimer Disease

Thursday, March 27 | 8:00AM - 11:15AM
Tau Function and Dysfunction in AD and Related Disorders
Room: Red Cloud Peak

Speaker 7 of 7
George S. Bloom, University of Virginia, USA
Short Talk: Tau-Dependent Microtubule Loss Induced by Pre-Fibrillar Beta-amyloid


Thursday, March 27 | 9:20AM - 9:40AM
Coffee Break
Room: Shavano Peak Foyer


Thursday, March 27 | 11:15AM - 1:00PM
Poster Setup
Room: Shavano/Torreys


Thursday, March 27 | 1:00PM - 10:00PM
Poster Viewing
Room: Shavano/Torreys


Thursday, March 27 | 4:30PM - 5:00PM
Coffee Available
Room: Shavano Peak Foyer


Thursday, March 27 | 5:00PM - 7:00PM
Biomarkers and Imaging
Room: Red Cloud Peak

Speaker 1 of 6
* David M. Holtzman, Washington University, USA

Thursday, March 27 | 5:00PM - 7:00PM
Biomarkers and Imaging
Room: Red Cloud Peak

Speaker 2 of 6
* Cynthia A. Lemere, Brigham and Women's Hospital, Harvard Medical School, USA

Thursday, March 27 | 5:00PM - 7:00PM
Biomarkers and Imaging
Room: Red Cloud Peak

Speaker 3 of 6
Anne M. Fagan, Washington University School of Medicine, USA
CSF and Amyloid Imaging Biomarkers in AD

Thursday, March 27 | 5:00PM - 7:00PM
Biomarkers and Imaging
Room: Red Cloud Peak

Speaker 4 of 6
Tony Wyss-Coray, Stanford University School of Medicine, USA
Plasma protein biomarkers for aging and Alzheimer's disease

Thursday, March 27 | 5:00PM - 7:00PM
Biomarkers and Imaging
Room: Red Cloud Peak

Speaker 5 of 6
Reisa A. Sperling, Brigham and Women's Hospital, Harvard Medical School, USA
Functional and Molecular Imaging in Early AD

Thursday, March 27 | 5:00PM - 7:00PM
Biomarkers and Imaging
Room: Red Cloud Peak

Speaker 6 of 6
Jessica Koenigsknecht-Talboo, Washington University, USA
Short Talk: Dynamic Imaging of Microglia and Abeta Deposition: Evidence of Rapid Responses Following Systemic Anti-Abeta Antibody Administration

Thursday, March 27 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Shavano/Torreys


Thursday, March 27 | 7:30PM - 10:00PM
Poster Session 3
Room: Shavano/Torreys


Friday, March 28 | 7:00AM - 8:00AM
Breakfast
Room: Shavano/Torreys


Friday, March 28 | 8:00AM - 11:15AM
Therapeutics
Room: Red Cloud Peak

Speaker 1 of 7
* Cynthia A. Lemere, Brigham and Women's Hospital, Harvard Medical School, USA

Friday, March 28 | 8:00AM - 11:15AM
Therapeutics
Room: Red Cloud Peak

Speaker 2 of 7
Ronald B. DeMattos, Lilly Research Laboratories, USA
Update on Active and Passive Immunotherapy

Friday, March 28 | 8:00AM - 11:15AM
Therapeutics
Room: Red Cloud Peak

Speaker 3 of 7
Gerald Koelsch, Astellas Pharma, USA
Beta-Secretase Inhibitor CTS-21166 Reduces Plasma Abeta40 in Human Subjects

Friday, March 28 | 8:00AM - 11:15AM
Therapeutics
Room: Red Cloud Peak

Speaker 4 of 7
JoAnne McLaurin, University of Toronto, Canada
Novel Small Molecule Therapies for AD

Friday, March 28 | 8:00AM - 11:15AM
Therapeutics
Room: Red Cloud Peak

Speaker 5 of 7
Takaomi C. Saido, RIKEN Brain Science Institute, Japan
N-Terminal Modification of Amyloid-beta Peptide, AbetaX-42, in Alzheimer's Disease and Mouse Models

Friday, March 28 | 8:00AM - 11:15AM
Therapeutics
Room: Red Cloud Peak

Speaker 6 of 7
Hans-Ulrich Demuth, Probiodrug AG, Germany
Short Talk: Prevention of Abeta3(pE)-42 Formation: A New Causative Treatment Paradigm in AD

Friday, March 28 | 8:00AM - 11:15AM
Therapeutics
Room: Red Cloud Peak

Speaker 7 of 7
Jonathan Thomas Megerian, Epix Pharmaceuticals, USA
Short Talk: Results of a Phase 2A Study of a Novel 5HT4 Agonist for the Treatment of Alzheimer’s Disease

Friday, March 28 | 9:20AM - 9:40AM
Coffee Break
Room: Shavano Peak Foyer


Friday, March 28 | 4:30PM - 5:00PM
Coffee Available
Room: Shavano Peak Foyer


Friday, March 28 | 5:00PM - 7:00PM
Therapeutics II
Room: Red Cloud Peak

Speaker 1 of 5
* David M. Holtzman, Washington University, USA

Friday, March 28 | 5:00PM - 7:00PM
Therapeutics II
Room: Red Cloud Peak

Speaker 2 of 5
Steven L. Wagner, TorreyPines Therapeutics, USA
Modulation of the Gamma Secretase Enzyme Complex with Orally Bioavailable Small Molecules

Friday, March 28 | 5:00PM - 7:00PM
Therapeutics II
Room: Red Cloud Peak

Speaker 3 of 5
Frank M. La Ferla, University of California, Irvine, USA
Reversing age-dependent memory impairments in a transgenic model of Alzheimer disease

Friday, March 28 | 5:00PM - 7:00PM
Therapeutics II
Room: Red Cloud Peak

Speaker 4 of 5
William James Ray, Merck & Co. Inc., USA
Targeting Pathways that Lead to the Accumulation of Amyloid

Friday, March 28 | 5:00PM - 7:00PM
Therapeutics II
Room: Red Cloud Peak

Speaker 5 of 5
Michael Bacher, Philipp-University Marburg, Germany
Short Talk: Administration of CNI-1493 inhibits Aß accumulation, amyloid plaque formation, and cognitive deterioration in an animal model of Alzheimer’s disease


Friday, March 28 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Shavano/Torreys


Friday, March 28 | 8:00PM - 11:00PM
Entertainment
Room: Shavano/Torreys


Friday, March 28 | 8:00PM - 11:00PM
Cash Bar
Room: Shavano/Torreys


Saturday, March 29 | 10:25AM - 10:25AM
Departure


*Session Chair.